HUP0302160A2 - GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények - Google Patents
GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0302160A2 HUP0302160A2 HU0302160A HUP0302160A HUP0302160A2 HU P0302160 A2 HUP0302160 A2 HU P0302160A2 HU 0302160 A HU0302160 A HU 0302160A HU P0302160 A HUP0302160 A HU P0302160A HU P0302160 A2 HUP0302160 A2 HU P0302160A2
- Authority
- HU
- Hungary
- Prior art keywords
- prodrug
- sorbitol dehydrogenase
- combination
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title abstract 2
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 title 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 abstract 3
- 208000028389 Nerve injury Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 230000008764 nerve damage Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000005230 Leg Ulcer Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 210000001328 optic nerve Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A jelen találmány tárgyát képezik a g-amino-butirsav (GABA), annakelőgyógyszere vagy az említett GABA-agonista vagy annak előgyógyszeregyógyszerészetileg elfogadható sója és szorbitot dehidrogenázinhibitor (SDI) vegyület, annak előgyógyszere vagy az említett SDI-vegyület és előgyógyszere gyógyszerészetileg elfogadható sója általalkotott gyógyszerkészítmények, a kombinációkat tartalmazó kitek,valamint ezeknek a kombinációknak a felhasználási eljárásai olyanemlősök, ideértve az embert is, kezelésére, amelyek olyancukorbetegséggel együttjáró szövődményektől szenvednek többek között,mint a cukorbetegséggel együttjáró idegbántalom, a vesebetegség, aszívizom betegség, a szemideghártya bántalom, a kis erek bántalma, anagy erek betegsége, a szürkehályog vagy a lábszárfekélyek. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25006900P | 2000-11-30 | 2000-11-30 | |
PCT/IB2001/002213 WO2002043762A2 (en) | 2000-11-30 | 2001-11-19 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0302160A2 true HUP0302160A2 (hu) | 2003-11-28 |
HUP0302160A3 HUP0302160A3 (en) | 2005-05-30 |
Family
ID=22946187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302160A HUP0302160A3 (en) | 2000-11-30 | 2001-11-19 | Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors |
Country Status (38)
Country | Link |
---|---|
US (1) | US6544998B2 (hu) |
EP (1) | EP1337271B1 (hu) |
JP (1) | JP2004514699A (hu) |
KR (1) | KR20030059290A (hu) |
CN (1) | CN1477975A (hu) |
AP (1) | AP2001002360A0 (hu) |
AR (1) | AR031431A1 (hu) |
AT (1) | ATE281181T1 (hu) |
AU (1) | AU2002215159A1 (hu) |
BG (1) | BG107774A (hu) |
BR (1) | BR0115783A (hu) |
CA (1) | CA2430298A1 (hu) |
CR (1) | CR6964A (hu) |
CZ (1) | CZ20031399A3 (hu) |
DE (1) | DE60106968T2 (hu) |
DO (1) | DOP2001000289A (hu) |
EA (1) | EA200300432A1 (hu) |
EC (1) | ECSP034624A (hu) |
EE (1) | EE200300248A (hu) |
ES (1) | ES2230378T3 (hu) |
HR (1) | HRP20030420A2 (hu) |
HU (1) | HUP0302160A3 (hu) |
IL (1) | IL155704A0 (hu) |
IS (1) | IS6786A (hu) |
MA (1) | MA26964A1 (hu) |
MX (1) | MXPA03004870A (hu) |
NO (1) | NO20032441L (hu) |
OA (1) | OA12534A (hu) |
PA (1) | PA8534101A1 (hu) |
PE (1) | PE20020597A1 (hu) |
PL (1) | PL365927A1 (hu) |
PT (1) | PT1337271E (hu) |
SK (1) | SK6192003A3 (hu) |
SV (1) | SV2003000751A (hu) |
TN (1) | TNSN01169A1 (hu) |
UY (1) | UY27042A1 (hu) |
WO (1) | WO2002043762A2 (hu) |
ZA (1) | ZA200303381B (hu) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
OA12604A (en) * | 2001-05-25 | 2006-06-08 | Warner Lambert Co | Liquid pharmaceutical composition. |
CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
KR20070020022A (ko) * | 2004-04-02 | 2007-02-16 | 임팩스 라보라토리즈, 인코포레이티드 | Gaba 수용체 효능제에 대한 제어 방출 제형 |
US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
EP2142529B1 (en) | 2007-04-27 | 2013-12-25 | Purdue Pharma LP | Trpv1 antagonists and uses thereof |
JP5452494B2 (ja) * | 2007-10-09 | 2014-03-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンフォチアミンと1または2種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物 |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | 眼疾患を治療する化合物および方法 |
WO2012050907A2 (en) * | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
RU2621708C2 (ru) | 2011-06-22 | 2017-06-07 | ПУРДЬЮ ФАРМА Эл. Пи. | Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CN114206349A (zh) | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
SG11202111822QA (en) * | 2019-05-07 | 2021-11-29 | Univ Miami | Treatment and detection of inherited neuropathies and associated disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
GR68380B (hu) | 1979-06-01 | 1981-12-28 | Wellcome Found | |
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
KR950703539A (ko) * | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
AU3503300A (en) * | 1999-02-24 | 2000-09-14 | Regents Of The University Of California, The | Gaba receptors mediate inhibition of t cell responses |
WO2000059510A1 (en) * | 1999-04-01 | 2000-10-12 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
ATE264311T1 (de) * | 1999-04-01 | 2004-04-15 | Pfizer Prod Inc | Verbindungen zur behandlung und vorsorge bei diabetes |
-
2001
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Application Discontinuation
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-19 EP EP01983739A patent/EP1337271B1/en not_active Expired - Lifetime
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Application Discontinuation
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-22 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302160A2 (hu) | GABA agonisták és szorbitol dehidrogenáz inhibitorok kombinációját tartalmazó gyógyszerkészítmények | |
ATE469674T1 (de) | 5-aminolävulinsäure-derivate zur behandlung von akne | |
CN110198708B (zh) | 用于组合疗法的药物组合物 | |
MA26946A1 (fr) | Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases. | |
BRPI0416628A (pt) | uso de compostos orgánicos | |
CY1108823T1 (el) | Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3 | |
HUP0301749A2 (hu) | Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk | |
IS2734B (is) | Pýrasólafleiður og notkun þar á, ásamt lyfjasamsetningum | |
NO20054958L (no) | Substitulerte aminokarboksylsyrer | |
BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
HUP0001286A2 (hu) | Karbazol-ecetsavat tartalmazó, kutyák fájdalmának és gyulladásának kezelésére alkalmas gyógyszerkészítmény | |
EA200500376A1 (ru) | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) | |
WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
BRPI0608654C1 (pt) | uso de 5-amino-1-b-d-(5-benzilamino-5-desóxi-1-b-d-ribofuranosil)imidazol-4-carboxamida, 5-amino-1-(5-amino-5-desóxi-b-d-ribofuranosil)imidazol-4-n-[(4-clorofenil)metil]carboxamida ou um sal dos mesmos | |
NO20051011L (no) | Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister | |
ATE305777T1 (de) | Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation | |
EA200801308A1 (ru) | Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик | |
WO2003048122A3 (en) | Inhibitors of cytosolic phospholipase a2 | |
EA200700406A1 (ru) | Производные хиназолина , применяемые для лечения поражений периферических артерий и в качестве ингибиторов фосфодиэстеразы | |
Benyahia et al. | Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents | |
JP2002105067A (ja) | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 | |
ATE384714T1 (de) | Pyrazolderivate | |
Shen et al. | Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension | |
NO20080860L (no) | Substituert propanamidderivat og farmasoytisk preparat som inneholder dette | |
EP1802297A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY YERSINIA SPP INFECTION |